Glytec, a leader in diabetes and insulin management software, has joined forces with pharmaceutical giant Roche to integrate Glytec's Glucommander software with Roche's cobas pulse blood glucose system. This collaboration, targeting both U.S. and global markets, aims to enhance hospital-based diabetes care by providing lab-quality blood glucose results and optimizing insulin dosing decisions. The cobas pulse system is noted for its accuracy across all patient populations, including neonates and those in intensive care, making it a versatile tool in managing inpatient diabetes.
This partnership aligns with Glytec's strategy to advance diabetes and insulin management by leveraging Roche's global reach and Glytec's established expertise. The combined effort is expected to improve patient outcomes, increase the cost-effectiveness of care, and enhance overall patient safety. Glytec's Chief Strategy Officer, Robby Booth, emphasized the importance of addressing global diabetes challenges, highlighting the collaboration's potential to make a significant impact on hospital diabetes management worldwide.
In recent developments, Glytec has been proactive in supporting CMS's new reporting requirements aimed at improving glycemic measures, which benefits underserved communities and strengthens value-based care initiatives. The company has also expanded its footprint through partnerships with healthcare institutions like Major Health Partners and the Cleveland Clinic, further solidifying its role in advancing insulin management and patient care.
Click here to read the original news story.